1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zong L, Abe M, Seto Y and Ji J: The
challenge of screening for early gastric cancer in China. Lancet.
388:26062016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Johnson LA and June CH: Driving
gene-engineered T cell immunotherapy of cancer. Cell Res. 27:38–58.
2017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Essand M and Loskog AS: Genetically
engineered T cells for the treatment of cancer. J Intern Med.
273:166–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Batlevi CL, Matsuki E, Brentjens RJ and
Younes A: Novel immunotherapies in lymphoid malignancies. Nat Rev
Clin Oncol. 13:25–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wei SM: Monoclonal antibodies against
gastric cancer and their selective reaction on various tissues.
Zhonghua Zhong Liu Za Zhi. 11:162–164. 1989.(In Chinese).
PubMed/NCBI
|
8
|
Xu G, Zhang M, Liu B, Li Z, Lin B, Xu X,
Jin M, Li J, Wu J, Dong Z, et al: Radioimmunoguided surgery in
gastric cancer using 131-I labeled monoclonal antibody 3H11. Semin
Surg Oncol. 10:88–94. 1994. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wang C, Wang Y, Su X, Lin B, Xu X, Zhang
M, Li J and Xu G: Iodine-125 labeled monoclonal antibody 3H11: In
radioimmunoguided surgery for primary gastric cancer. Zhonghua Wai
Ke Za Zhi. 38:507–509. 2000.(In Chinese). PubMed/NCBI
|
10
|
Li J, Wang Y, Li QX, Wang YM, Xu JJ and
Dong ZW: Cloning of 3H11 mAb variable region gene and expression of
3H11 human-mouse chimeric light Chain. World J Gastroenterol.
4:41–44. 1998. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chen D and Shou C: Molecular cloning of a
tumor-associated antigen recognized by monoclonal antibody 3H11.
Biochem Biophys Res Commun. 280:99–103. 2001. View Article : Google Scholar : PubMed/NCBI
|
12
|
Liu X, Ory V, Chapman S, Yuan H, Albanese
C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, et al:
ROCK inhibitor and feeder cells induce the conditional
reprogramming of epithelial cells. Am J Pathol. 180:599–607. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Ye J, Ma N, Madden TL and Ostell JM:
IgBLAST: An immunoglobulin variable domain sequence analysis tool.
Nucleic Acids Res. 41:(Web Server Issue). W34–W40. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Enblad G, Karlsson H and Loskog AS: CAR
T-Cell therapy: The role of physical barriers and immunosuppression
in lymphoma. Hum Gene Ther. 26:498–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Tang XY, Sun Y, Zhang A, Hu GL, Cao W,
Wang DH, Zhang B and Chen H: Third-generation CD28/4-1BB chimeric
antigen receptor T cells for chemotherapy relapsed or refractory
acute lymphoblastic leukaemia: A non-randomised, open-label phase I
trial protocol. BMJ Open. 6:e0139042016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ozawa K: Current status and future
development of CAR-T gene therapy. Rinsho Ketsueki. 56:2180–2185.
2015.(In Japanese). PubMed/NCBI
|
17
|
Davenport AJ, Jenkins MR, Ritchie DS,
Prince HM, Trapani JA, Kershaw MH, Darcy PK and Neeson PJ: CAR-T
cells are serial killers. Oncoimmunology. 4:e10536842015.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Schneider U, Schwenk HU and Bornkamm G:
Characterization of EBV-genome negative ‘null’ and ‘T’ cell lines
derived from children with acute lymphoblastic leukemia and
leukemic transformed non-Hodgkin lymphoma. Int J Cancer.
19:621–626. 1977. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kobayashi E, Kishi H, Ozawa T, Hamana H,
Nakagawa H, Jin A, Lin Z and Muraguchi A: A chimeric antigen
receptor for TRAIL-receptor 1 induces apoptosis in various types of
tumor cells. Biochem Biophys Res Commun. 453:798–803. 2014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Shirasu N, Shibaguci H and Kuroki M,
Yamada H and Kuroki M: Construction and molecular characterization
of human chimeric T-cell antigen receptors specific for
carcinoembryonic antigen. Anticancer Res. 30:2731–2738.
2010.PubMed/NCBI
|
21
|
Jamnani FR, Rahbarizadeh F, Shokrgozar MA,
Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L and Moghimi
SM: T cells expressing VHH-directed oligoclonal chimeric HER2
antigen receptors: Towards tumor-directed oligoclonal T cell
therapy. Biochim Biophys Acta. 1840:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Khaleghi S, Rahbarizadeh F, Ahmadvand D,
Rasaee MJ and Pognonec P: A caspase 8-based suicide switch induces
apoptosis in nanobody-directed chimeric receptor expressing T
cells. Int J Hematol. 95:434–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhang Q, Wang H, Li H, Xu J, Tian K, Yang
J, Lu Z and Zheng J: Chimeric antigen receptor-modified T Cells
inhibit the growth and metastases of established tissue
factor-positive tumors in NOG mice. Oncotarget. 8:9488–9499.
2017.PubMed/NCBI
|
24
|
Pule MA, Savoldo B, Myers GD, Rossig C,
Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al:
Virus-specific T cells engineered to coexpress tumor-specific
receptors: Persistence and antitumor activity in individuals with
neuroblastoma. Nat Med. 14:1264–1270. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zuccolotto G, Fracasso G, Merlo A,
Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S,
Colombatti M, Zanovello P and Rosato A: PSMA-specific
CAR-engineered T cells eradicate disseminated prostate cancer in
preclinical models. PLoS One. 9:e1094272014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Craddock JA, Lu A, Bear A, Pule M, Brenner
MK, Rooney CM and Foster AE: Enhanced tumor trafficking of GD2
chimeric antigen receptor T cells by expression of the chemokine
receptor CCR2b. J Immunother. 33:780–788. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Caruana I, Savoldo B, Hoyos V, Weber G,
Liu H, Kim ES, Ittmann MM, Marchetti D and Dotti G: Heparanase
promotes tumor infiltration and antitumor activity of
CAR-redirected T lymphocytes. Nat Med. 21:524–529. 2015. View Article : Google Scholar : PubMed/NCBI
|